×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RLMD – relmada therapeutics, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RLMD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/30
06:07 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
1/29
07:41 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Zacks Research to a "hold" rating.
Low
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Zacks Research to a "hold" rating.
1/23
08:04 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $8.00 price target on the stock.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $8.00 price target on the stock.
1/12
07:20 am
rlmd
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications [Yahoo! Finance]
Medium
Report
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications [Yahoo! Finance]
1/12
07:00 am
rlmd
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
Low
Report
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
12/23
09:37 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Low
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
12/21
08:06 pm
rlmd
Relmada Therapeutics (NASDAQ:RLMD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
12/3
07:30 am
rlmd
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Low
Report
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2025
04:01 pm
rlmd
relmada therapeutics, inc.
MISS
Report
-0.5%
relmada therapeutics, inc.
8/7/2025
04:05 pm
rlmd
relmada therapeutics, inc.
MISS
Report
-2.4%
relmada therapeutics, inc.
5/12/2025
04:01 pm
rlmd
relmada therapeutics, inc.
MISS
Report
-2.1%
relmada therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/30
05:14 pm
rlmd
Form 424B5 RELMADA THERAPEUTICS,
Low
Report
Form 424B5 RELMADA THERAPEUTICS,
12/16
09:31 am
rlmd
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: TRAVERSA SERGIO
Low
Report
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: TRAVERSA SERGIO
12/16
09:30 am
rlmd
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: Ence Chuck
Medium
Report
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: Ence Chuck
12/16
09:30 am
rlmd
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: Shenouda Maged
Low
Report
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: Shenouda Maged
12/16
09:29 am
rlmd
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: GLASSPOOL JOHN
Medium
Report
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: GLASSPOOL JOHN
12/16
09:29 am
rlmd
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: Fedeli Fabiana
Medium
Report
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: Fedeli Fabiana
12/16
09:29 am
rlmd
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: Kelly Paul Edward
Medium
Report
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: Kelly Paul Edward
12/16
09:28 am
rlmd
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: CASAMENTO CHARLES J
Medium
Report
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: CASAMENTO CHARLES J
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/14
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
134.0%
10/18 Form 8-K RELMADA THERAPEUTICS, For: Oct 17 52.4%
12/4 Relmada prices $100M equity offering [Seeking Alpha] 49.8%
3/18 Form 4 RELMADA THERAPEUTICS, For: Mar 17 Filed by: CASAMENTO CHARLES J 14.7%
3/16 Form 3 RELMADA THERAPEUTICS, For: Mar 09 Filed by: Wessel Thomas 10.6%
10/28 Form S-3/A RELMADA THERAPEUTICS, 10.5%
3/24 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development 10.0%
5/16 Form D RELMADA THERAPEUTICS, 8.2%
3/31 Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety 7.4%
5/15 Form 4 RELMADA THERAPEUTICS, For: May 14 Filed by: Kelly Paul Edward 7.1%
10/18 Form 8-K RELMADA THERAPEUTICS, For: Oct 17 52.4%
12/4 Relmada prices $100M equity offering [Seeking Alpha] 49.8%
3/18 Form 4 RELMADA THERAPEUTICS, For: Mar 17 Filed by: CASAMENTO CHARLES J 14.7%
3/16 Form 3 RELMADA THERAPEUTICS, For: Mar 09 Filed by: Wessel Thomas 10.6%
10/28 Form S-3/A RELMADA THERAPEUTICS, 10.5%
3/24 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development 10.0%
5/16 Form D RELMADA THERAPEUTICS, 8.2%
3/31 Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety 7.4%
5/15 Form 4 RELMADA THERAPEUTICS, For: May 14 Filed by: Kelly Paul Edward 7.1%
TOP News Decliners
10/17
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
-18.0%
6/20 Form 8-K RELMADA THERAPEUTICS, For: Jun 14 -16.0%
10/21 Form 8-K RELMADA THERAPEUTICS, For: Oct 15 -12.3%
7/10 Form D/A RELMADA THERAPEUTICS, -10.5%
1/31 Form DEF 14A RELMADA THERAPEUTICS, For: Mar 06 -9.7%
3/9 Form 8-K RELMADA THERAPEUTICS, For: Mar 06 -8.7%
3/9 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development -8.6%
10/24 Form EFFECT RELMADA THERAPEUTICS, -7.1%
5/1 Relmada Therapeutics Inc (OTCMKTS: RLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.0%
4/21 Relmada Therapeutics Inc (OTCMKTS: RLMD) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -6.0%
6/20 Form 8-K RELMADA THERAPEUTICS, For: Jun 14 -16.0%
10/21 Form 8-K RELMADA THERAPEUTICS, For: Oct 15 -12.3%
7/10 Form D/A RELMADA THERAPEUTICS, -10.5%
1/31 Form DEF 14A RELMADA THERAPEUTICS, For: Mar 06 -9.7%
3/9 Form 8-K RELMADA THERAPEUTICS, For: Mar 06 -8.7%
3/9 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development -8.6%
10/24 Form EFFECT RELMADA THERAPEUTICS, -7.1%
5/1 Relmada Therapeutics Inc (OTCMKTS: RLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.0%
4/21 Relmada Therapeutics Inc (OTCMKTS: RLMD) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: